These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37098163)

  • 1. Symptoms of illness during travel and risk factors for non-adherence to malaria prophylaxis-a cross-sectional study in travellers from Germany.
    Reinsberg F; Moehlmann MW; Krumkamp R; Landsmann L; Heitkamp C; Jochum J; Addo M; Ramharter M; Radt C; Rothe C; Vinnemeier C; Kreuels B
    J Travel Med; 2023 May; 30(3):. PubMed ID: 37098163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mefloquine for preventing malaria during travel to endemic areas.
    Tickell-Painter M; Maayan N; Saunders R; Pace C; Sinclair D
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD006491. PubMed ID: 29083100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of twice a week prophylaxis with atovaquone-proguanil (Malarone®) in long-term travellers to West Africa.
    Lachish T; Bar-Meir M; Eisenberg N; Schwartz E
    J Travel Med; 2016 Jun; 23(6):. PubMed ID: 27625401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abbreviated atovaquone-proguanil prophylaxis regimens in travellers after leaving malaria-endemic areas: A systematic review.
    Savelkoel J; Binnendijk KH; Spijker R; van Vugt M; Tan K; Hänscheid T; Schlagenhauf P; Grobusch MP
    Travel Med Infect Dis; 2018; 21():3-20. PubMed ID: 29242073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travellers: a randomised, double-blind study. Malarone International Study Team.
    Høgh B; Clarke PD; Camus D; Nothdurft HD; Overbosch D; Günther M; Joubert I; Kain KC; Shaw D; Roskell NS; Chulay JD;
    Lancet; 2000 Dec; 356(9245):1888-94. PubMed ID: 11130385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-free Holidays: Compliance, Tolerability, and Acceptability of a 3-Day Atovaquone/Proguanil Schedule for Pretravel Malaria Chemoprophylaxis in Australian Travelers.
    Lau CL; Ramsey L; Mills LC; Furuya-Kanamori L; Mills DJ
    Clin Infect Dis; 2019 Jun; 69(1):137-143. PubMed ID: 30281083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malaria Surveillance - United States, 2016.
    Mace KE; Arguin PM; Lucchi NW; Tan KR
    MMWR Surveill Summ; 2019 May; 68(5):1-35. PubMed ID: 31099769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study.
    Schlagenhauf P; Tschopp A; Johnson R; Nothdurft HD; Beck B; Schwartz E; Herold M; Krebs B; Veit O; Allwinn R; Steffen R
    BMJ; 2003 Nov; 327(7423):1078. PubMed ID: 14604928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative benefit of malaria chemoprophylaxis modelled in United Kingdom travellers.
    Toovey S; Nieforth K; Smith P; Schlagenhauf P; Adamcova M; Tatt I; Tomianovic D; Schnetzler G
    Travel Med Infect Dis; 2014; 12(6 Pt B):726-32. PubMed ID: 25443997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-adherence to malaria prophylaxis: The influence of travel-related and psychosocial factors.
    Hoefnagel JGM; Massar K; Hautvast JLA
    J Infect Public Health; 2020 Apr; 13(4):532-537. PubMed ID: 31704047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effects and compliance with mefloquine or proguanil antimalarial chemoprophylaxis.
    Hoebe C; de Munter J; Thijs C
    Eur J Clin Pharmacol; 1997; 52(4):269-75. PubMed ID: 9248763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term health outcomes among Returned Peace Corps Volunteers after malaria prophylaxis, 1995-2014.
    Tan KR; Henderson SJ; Williamson J; Ferguson RW; Wilkinson TM; Jung P; Arguin PM
    Travel Med Infect Dis; 2017; 17():50-55. PubMed ID: 28487213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malaria Surveillance - United States, 2018.
    Mace KE; Lucchi NW; Tan KR
    MMWR Surveill Summ; 2022 Sep; 71(8):1-35. PubMed ID: 36048717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of factors affecting adherence to malaria chemoprophylaxis amongst travellers from non-endemic countries.
    Ahluwalia J; Brooks SK; Weinman J; Rubin GJ
    Malar J; 2020 Jan; 19(1):16. PubMed ID: 31931813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Malaria--chemoprophylaxis 2001].
    Hatz FR; Beck B; Blum J; Funk M; Furrer H; Genton B; Holzer B; Loutan L; Markwalder K; Raeber PA; Schlagenhauf P; Siegl G; Steffen R; Stürchler D; Wyss R
    Ther Umsch; 2001 Jun; 58(6):347-51. PubMed ID: 11441694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cluster of Plasmodium vivax malaria in an expedition group to Ethiopia: prophylactic efficacy of atovaquone/proguanil on liver stages of P. vivax.
    Mavrogordato A; Lever AM
    J Infect; 2012 Sep; 65(3):269-74. PubMed ID: 22609735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hair concentrations of anti-malarials in returned travellers-the HAIR study: Proof of principle analysis.
    Steiner R; Kaulich A; Müller D; Schlagenhauf P
    Travel Med Infect Dis; 2023; 54():102590. PubMed ID: 37209974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Malaria chemoprophylaxis].
    Petersen JE
    Ugeskr Laeger; 2005 Oct; 167(42):3984-7. PubMed ID: 16232397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.
    McKeage K; Scott L
    Drugs; 2003; 63(6):597-623. PubMed ID: 12656656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuing atovaquone/proguanil prophylaxis ad-hoc post-exposure and during-travel dose-sparing prophylactic regimens against P. falciparum malaria: An update with pointers for future research.
    Schnyder JL; de Jong HK; Schlagenhauf P; Borrmann S; Hanscheid T; Grobusch MP
    Travel Med Infect Dis; 2022; 49():102365. PubMed ID: 35661741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.